.webp)
.webp)
.webp)
.webp)
How a manufacturer moves product to market determines who holds the licenses, who carries the DSCSA obligations, and who is liable when something breaks down.
Self-distribution and a third-party logistics provider are not interchangeable, and the difference matters well before the first shipment.
A 3PL handles warehousing, order management, and outbound shipping on behalf of the manufacturer without taking ownership of the product. The manufacturer retains title and regulatory responsibility.
For manufacturers not ready, or not willing, to build and manage their own warehousing and fulfillment infrastructure, a 3PL offers an established operational foundation without the capital investment.
Under DSCSA, 3PLs are a distinct category from wholesale distributors with their own authorized trading partner obligations, including annual licensure reporting to FDA. These are the 3PL's obligations, but the manufacturer is exposed if its 3PL is not meeting them.
State licensing: a 3PL needs to be licensed in almost every state where it warehouses or ships. Some states have a specific 3PL permit; others license 3PLs as wholesale distributors; some don't regulate 3PLs at all. The manufacturer needs to verify its 3PL's license status in every relevant state before the contract is signed.
If a 3PL loses a license in a state that regulates 3PLs, the manufacturer's ability to distribute there could be impacted regardless of the manufacturer's own license status.
The manufacturer owns the product, controls the warehouse, and ships directly to customers under its own operating authority.
Most states do not require a manufacturer distributing its own products to hold a separate wholesale distributor license as the manufacturer license covers the activity. A small number of states require both. Confirming the correct license type before the first shipment is essential as operating without the right license creates the same exposure as any other missing license.
DSCSA obligations expand accordingly. The manufacturer takes on full wholesale distributor obligations, including transaction documentation, serialization and verification, suspect product procedures, and annual licensure reporting to FDA.
Self-distribution also requires warehouse infrastructure, order management systems, cold chain capability if applicable, and the workforce to run the operations. For a manufacturer just starting up, this is rarely feasible at launch.
Some 3PLs temporarily take title to product as part of a commercialization structure. Under this model, a 3PL acts as a wholesale distributor by taking title, and requires wholesale licenses accordingly. This shifts the primary state licensing burden to the 3PL, reducing the number of states where the manufacturer must hold its own licenses.
For virtual manufacturers, the title model can shrink the state licensing footprint. The tradeoff is cost, as title model fees grow with revenue. For high-volume products, those fees can add up quickly, so modeling the cost against the licensing savings before committing is worthwhile.
It's also worth noting that 17 states require manufacturer licenses, and we recommend licensing in another 5, because the manufacturer's name is on the label and its product ends up in that state regardless of who holds title.
In these states, the title model doesn't reduce the manufacturer's licensing burden the way it does elsewhere. We recently covered this in When Your Name on the Label Becomes a License Requirement.
Drop shipment. A manufacturer sells to a wholesale distributor who sells to a pharmacy, but product ships directly from the manufacturer to the pharmacy. All three parties carry DSCSA transaction documentation obligations even though the distributor never touched the product.
Cold chain. Manufacturers distributing temperature-sensitive products need a 3PL with validated cold chain infrastructure or they need to develop this capability on their own. Validation documentation falls on the manufacturer regardless of who runs the operation.
Most manufacturers launching a new product start with a 3PL. It is faster to standup, requires less capital investment, and puts infrastructure in the hands of someone who does it for a living.
Self-distribution makes more sense once volume justifies the fixed cost.
The title model is a specific tool for virtual manufacturers seeking the smallest possible licensing footprint, although the value of such a model is dropping as more states require the manufacturer to obtain a license in their state regardless of whether they sell directly into the state.
The distribution structure you choose determines who holds the licenses and who files the DSCSA reports. Knowing which model is right for your operation is only half the equation. Once decided, you must start the additional work of confirming that every partner in the chain is properly licensed, in every relevant state, before product moves is what keeps shipments flowing and trading partner relationships intact.
Receive additional news and insights about the US pharmaceutical and medical device supply chain from LighthouseAI.
About the Author
Sandy Carter is the Director of Intelligence, Research and Development with LighthouseAI and has over 10 years of experience in the pharmaceutical life sciences industry, specializing in high-quality compliance research across manufacturers, wholesalers, and 3PLs.
.svg){kind=small}
